News | Sutro Biopharma, Inc.

2022 Wells Fargo Healthcare Conference – Presentation

2022 Wells Fargo Healthcare Conference – Presentation Webcast...

Sutro Biopharma to Present at the 2022 Wells Fargo Healthcare Conference

Sutro Biopharma to Present at the 2022 Wells Fargo Healthcare Conference SOUTH SAN FRANCISCO, Calif., September 1, 2022 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody...

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

News, Press Releases

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., August 19, 2022 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format...

Sutro Biopharma Reports Second Quarter 2022 Financial Results, Business Highlights and Anticipated Milestones

News, Press Releases

Sutro Biopharma Reports Second Quarter 2022 Financial Results, Business Highlights and Anticipated Milestones – Collaboration with Astellas on discovery and development of iADCs for up to three targets, includes an upfront payment of $90 million and $422.5...

Sutro Biopharma to Present at the 2022 Wedbush PacGrow Healthcare Conference

Events, News, Presentations, Press Releases

Sutro Biopharma to Present at the 2022 Wedbush PacGrow Healthcare Conference SOUTH SAN FRANCISCO, Calif., August 3, 2022 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody...

Sutro Biopharma Achieves “First in Human” Milestone in Cytokine Derivatives Collaboration with Merck

News, Press Releases

Sutro Biopharma Achieves “First in Human” Milestone in Cytokine Derivatives Collaboration with Merck SOUTH SAN FRANCISCO, Calif., July 26, 2022 – Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage oncology company pioneering...